FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Neil Kay

Research Profile

Disorders

Anatomy

Procedures

Chemicals & Drugs

Physiology

Disease Progression

Concepts & Ideas

Co-author Network

Publications

TOP 3
Tait D Shanafelt; Han W Tun; Clive S Zent; Deborah Bowen; Timothy G Call; Curtis A Hanson; Diane F Jelinek; Betsy Laplant; Jose F Leis; Adam Pettinger; Alan G Ramsay; Neil E Kay
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Tait D Shanafelt; Chung S Yang; Clive S Zent; Deborah A Bowen; Timothy G Call; Charles Erlichman; Asish K Ghosh; Diane F Jelinek; Betsy LaPlant; Kristina Laumann; Mao-Jung Lee; Jose F Leis; Connie Lesnick; Michelle Roos; Neil E Kay
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
J Moreira; Kari G Rabe; Susan M Schwager; D A Bowen; Timothy G Call; J R Cerhan; Curtis A Hanson; Diane F Jelinek; Neil E Kay; J F Leis; S L Slager; J W Wilson; Tait D Shanafelt
Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Neil Kay (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Tait D Shanafelt; Han W Tun; Clive S Zent; Deborah Bowen; Timothy G Call; Curtis A Hanson; Diane F Jelinek; Betsy Laplant; Jose F Leis; Adam Pettinger; Alan G Ramsay; Neil E Kay
Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Blood 2013;121(20):4137-41.
2013: Tait D Shanafelt; Chung S Yang; Clive S Zent; Deborah A Bowen; Timothy G Call; Charles Erlichman; Asish K Ghosh; Diane F Jelinek; Betsy LaPlant; Kristina Laumann; Mao-Jung Lee; Jose F Leis; Connie Lesnick; Michelle Roos; Neil E Kay
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Cancer 2013;119(2):363-70.
2013: J Moreira; Kari G Rabe; Susan M Schwager; D A Bowen; Timothy G Call; J R Cerhan; Curtis A Hanson; Diane F Jelinek; Neil E Kay; J F Leis; S L Slager; J W Wilson; Tait D Shanafelt
Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls.
Leukemia 2013;27(1):136-41.
2012: Susan L Slager; Celine M Vachon; Alice H Wang; J Brice Weinberg; Sara J Achenbach; Nicholas K Akers; Paige M Bracci; Timothy G Call; Nicola J Camp; Lucia Conde; Julie M Cunningham; Martha Glenn; Neil E Kay; Mark C Lanasa; Jose F Leis; Brian Link; Shannon K McDonnell; Anne J Novak; Kari G Rabe; Sylvia Sanchez; Daniel J Serie; Tait D Shanafelt; Fenna M C Sille; Christine F Skibola; James R Cerhan
Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes.
British journal of haematology 2012;159(5):572-6.
2012: James R Cerhan; Julie M Cunningham; Ahmet Dogan; Zachary S Fredericksen; Thomas M Habermann; Neil E Kay; Mark Liebow; Anne J Novak; Stephen M Ansell; Yan W Asmann; Alice H Wang; Thomas E Witzig; Susan L Slager
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(10):1799-806.
2012: Esteban Braggio; John C Byrd; Jeanette E Eckel-Passow; M Barrett; Diane F Jelinek; Neil E Kay; T Sassoon; Tait D Shanafelt; Stephanie A Smoley; Renee C Tschumper; Daniel L Van Dyke; S VanWier; Rafael Fonseca
Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.
Leukemia 2012;26(7):1698-701.
2012: Tait D Shanafelt; Susan L Slager; Carrie A Thompson; Thomas E Witzig; Clive S Zent; David J Inwards; Neil E Kay; Jose F Leis; Kari G Rabe; Susan M Schwager; Deborah A Bowen; Timothy G Call
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Cancer 2012;118(7):1827-37.
2012: Clive S Zent; Thomas E Witzig; James E Wooldridge; Zuhair K Ballas; Deborah A Bowen; Timothy G Call; Neil E Kay; Brian K Link; Tait D Shanafelt; Brian J Smith; George J Weiner
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.
Leukemia & lymphoma 2012;53(2):211-7.
2011: Marek Mraz; Anne J Novak; Stephen M Ansell; Amy K Church; Diane F Jelinek; Neil E Kay; Sarka Pospisilova; Thomas E Witzig; Xiaosheng Wu; Clive S Zent; Grzegorz S Nowakowski
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
British journal of haematology 2011;155(1):53-64.
2011: Matthew J Maurer; Kari G Rabe; Susan L Slager; Thomas E Witzig; Clive S Zent; Cristine Allmer; Timothy G Call; James R Cerhan; Curtis A Hanson; Jerry A Katzmann; Neil E Kay; Brian K Link; Tait D Shanafelt
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.
Blood 2011;118(10):2821-6.
2011: Xiaosheng Wu; Stephanie A Smoley; Mark A Peterson; Denise K Walters; Bonnie K Arendt; Grzegorz S Nowakowski; Daniel L Van Dyke; Neil E Kay; Diane F Jelinek
Biological evaluation of CpG stimulation of normal human B-cells: implications for B-cell biology and cytogenetic analysis of CLL B-cells.
British journal of haematology 2011;153(3):402-5.
2011: Susan L Slager; Kari G Rabe; Sara J Achenbach; Celine M Vachon; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Z Rassenti; Jose F Leis; Nicola J Camp; Martha Glenn; Neil E Kay; Julie M Cunningham; Curtis A Hanson; Gerald E Marti; J Brice Weinberg; Vicki A Morrison; Brian K Link; Timothy G Call; Neil E Caporaso; James R Cerhan
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
Blood 2011;117(6):1911-6.
2011: Tait D Shanafelt; Matthew T Drake; Matthew J Maurer; Cristine Allmer; Kari G Rabe; Susan L Slager; George J Weiner; Timothy G Call; Brian K Link; Clive S Zent; Neil E Kay; Curtis A Hanson; Thomas E Witzig; James Cerhan
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.
Blood 2011;117(5):1492-8.
2011: Muller Fabbri; Arianna Bottoni; Masayoshi Shimizu; Riccardo Spizzo; Milena S Nicoloso; Simona Rossi; Elisa Barbarotto; Amelia Cimmino; Brett Adair; Sylwia E Wojcik; Nicola Valeri; Federica Calore; Deepa Sampath; Francesca Fanini; Ivan Vannini; Gerardo Musuraca; Marie Dell'Aquila; Hansjuerg Alder; Ramana V Davuluri; Laura Rassenti; Massimo Negrini; Tatsuya Nakamura; Dino Amadori; Neil E Kay; Kanti R Rai; Michael J Keating; Thomas J Kipps; George A Calin; Carlo M Croce
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
JAMA : the journal of the American Medical Association 2011;305(1):59-67.
2011: Albert Gutierrez; Neil E Kay; Renee C Tschumper; Clive S Zent; Bonnie K Arendt; Diane F Jelinek
Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression.
PloS one 2011;6(10):e26056.
2011: James Cerhan; Julie M Cunningham; Zachary S Fredericksen; Thomas M Habermann; Neil E Kay; William R Macon; Tait D Shanafelt; Susan L Slager; Alice H Wang; Thomas E Witzig; Stephen M Ansell; Timothy G Call; Mark Liebow
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.
International journal of molecular epidemiology and genetics 2011;2(2):95-113.
2010: Neil E Kay; Jeanette E Eckel-Passow; Esteban Braggio; Scott Vanwier; Tait D Shanafelt; Daniel L Van Dyke; Diane F Jelinek; Renee C Tschumper; Thomas Kipps; John C Byrd; Rafael Fonseca
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy.
Cancer genetics and cytogenetics 2010;203(2):161-8.
2010: Stephanie A Smoley; Daniel L Van Dyke; Neil E Kay; Nyla A Heerema; Marie L Dell' Aquila; Paola Dal Cin; Prasad R K Koduru; Ayala Aviram; Laura Rassenti; John C Byrd; Kanti R Rai; Jennifer R Brown; Andrew W Greaves; Jeanette Eckel-Passow; Donna Neuberg; Thomas J Kipps; Gordon W Dewald
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium.
Cancer genetics and cytogenetics 2010;203(2):141-8.
2010: Nyla A Heerema; John C Byrd; Paola S Dal Cin; Marie L Dell' Aquila; Prasad R K Koduru; Ayala Aviram; Stephanie A Smoley; Laura Rassenti; Andrew W Greaves; Jennifer R Brown; Kanti R Rai; Thomas J Kipps; Neil E Kay; Daniel L Van Dyke
Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.
Cancer genetics and cytogenetics 2010;203(2):134-40.
2010: Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.
Cancer 2010;116(20):4777-87.
2010: Neil E Kay; Wenting Wu; Brian Kabat; Betsy LaPlant; Thomas S Lin; John C Byrd; Diane F Jelinek; Michael R Grever; Clive S Zent; Timothy G Call; Tait D Shanafelt
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia.
Cancer 2010;116(9):2180-7.
2010: Susan L Slager; Lynn R Goldin; Sara S Strom; Mark C Lanasa; Logan G Spector; Laura Rassenti; Jose F Leis; Nicola J Camp; Neil E Kay; Celine M Vachon; Martha Glenn; J Brice Weinberg; Kari G Rabe; Julie M Cunningham; Sara J Achenbach; Curtis A Hanson; Gerald E Marti; Timothy G Call; Neil E Caporaso; James R Cerhan
Genetic susceptibility variants for chronic lymphocytic leukemia.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010;19(4):1098-102.
2010: Deborah A Bowen; Timothy G Call; Tait D Shanafelt; Neil E Kay; Susan M Schwager; Megan S Reinalda; Kari G Rabe; Susan L Slager; Clive S Zent
Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.
Leukemia & lymphoma 2010;51(4):620-7.
2010: Clive S Zent; Neil E Kay
Autoimmune complications in chronic lymphocytic leukaemia (CLL).
Best practice & research. Clinical haematology 2010;23(1):47-59.
2010: Daniel L Van Dyke; Tait D Shanafelt; Timothy G Call; Clive S Zent; Stephanie A Smoley; Kari G Rabe; Susan M Schwager; Jessica C Sonbert; Susan L Slager; Neil E Kay
A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia.
British journal of haematology 2010;148(4):544-50.
2010: Roxana S Dronca; Dragan Jevremovic; Curtis A Hanson; Kari G Rabe; Tait D Shanafelt; William Morice; Timothy G Call; Neil E Kay; Charles S Collins; Susan M Schwager; Susan L Slager; Clive S Zent
CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.
Cytometry. Part B, Clinical cytometry 2010;78 Suppl 1():S35-41.
2009: Wei Ding; Grzegorz S Nowakowski; Traci R Knox; Justin C Boysen; Mary L Maas; Susan M Schwager; Wenting Wu; Linda E Wellik; Allan B Dietz; Asish K Ghosh; Charla R Secreto; Kay L Medina; Tait D Shanafelt; Clive S Zent; Timothy G Call; Neil E Kay
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression.
British journal of haematology 2009;147(4):471-83.
2009: Martha Q Lacy; Susanna Jacobus; Emily Blood; Neil E Kay; S Vincent Rajkumar; Philip R Greipp
Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
Leukemia research 2009;33(11):1485-9.
2009: Tait D Shanafelt; John C Byrd; Betsy LaPLant; Clive S Zent; Tim Call; Charla Secreto; Michael R Grever; Thomas S Lin; Neil E Kay
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
British journal of haematology 2009;146(6):660-4.
2009: Tait D Shanafelt; Neil E Kay; Kari G Rabe; Timothy G Call; Clive S Zent; Kami Maddocks; Greg Jenkins; Diane F Jelinek; William Morice; Justin Boysen; Susan M Schwager; Deborah Bowen; Susan L Slager; Curtis A Hanson
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3959-63.
2009: Tait D Shanafelt; Timothy G Call; Clive S Zent; Betsy LaPlant; Deborah A Bowen; Michelle Roos; Charla R Secreto; Asish K Ghosh; Brian Kabat; Mao-Jung Lee; Chung S Yang; Diane F Jelinek; Charles Erlichman; Neil E Kay
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3808-14.
2009: Clive S Zent; Wei Ding; Megan S Reinalda; Susan M Schwager; James D Hoyer; Deborah A Bowen; Diane F Jelinek; Renee C Tschumper; Timothy G Call; Tait D Shanafelt; Neil E Kay; Susan L Slager
Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.
Leukemia & lymphoma 2009;50(8):1261-8.
2009: Nicole Lamanna; Neil E Kay
Pentostatin treatment combinations in chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O 2009;7(6):386-92.
2009: James Cerhan; Anne J Novak; Zachary S Fredericksen; Alice H Wang; Mark Liebow; Timothy G Call; Ahmet Dogan; Thomas E Witzig; Stephen M Ansell; Thomas M Habermann; Neil E Kay; Susan L Slager
Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.
British journal of haematology 2009;145(5):614-23.
2009: Asish K Ghosh; Tait D Shanafelt; Amelia Cimmino; Cristian Taccioli; Stefano Volinia; Chang-gong liu; George A Calin; Carlo M Croce; Denise A Chan; Amato J Giaccia; Charla Secreto; Linda E Wellik; Yean K Lee; Debabrata Mukhopadhyay; Neil E Kay
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.
Blood 2009;113(22):5568-74.
2009: Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William Morice; Justin Boysen; Liam Zakko; Susan M Schwager; Susan L Slager; Curtis A Hanson
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.
Blood 2009;113(18):4188-96.
2009: Grzegorz S Nowakowski; James D Hoyer; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nancy D Bone; Betsy Laplant; Gordon W Dewald; Renee C Tschumper; Diane F Jelinek; Thomas E Witzig; Neil E Kay
Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1844-9.
2009: Neil E Kay; Tait D Shanafelt; Timothy G Call; Wenting Wu; Betsy R Laplant
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.
Leukemia & lymphoma 2009;50(4):588-92.
2009: Asish K Ghosh; Neil E Kay; Charla R Secreto; Tait D Shanafelt
Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1250-8.
2009: Tait D Shanafelt; Deborah A Bowen; Chaya Venkat; Susan L Slager; Clive S Zent; Neil E Kay; Megan Reinalda; Han Tun; Jeff A Sloan; Timothy G Call
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia.
Leukemia research 2009;33(2):263-70.
2009: Tait D Shanafelt; Greg Jenkins; Timothy G Call; Clive S Zent; Susan L Slager; Deborah A Bowen; Susan M Schwager; Curtis A Hanson; Diane F Jelinek; Neil E Kay
Validation of a new prognostic index for patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):363-72.
2009: Farrukh T Awan; Neil E Kay; Melanie E Davis; Wenting Wu; Susan M Geyer; Nelson Leung; Diane F Jelinek; Renee C Tschumper; Charla R Secreto; Thomas S Lin; Michael R Grever; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nyla A Heerema; Gerard Lozanski; John C Byrd; David M Lucas
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
Blood 2009;113(3):535-7.
2009: Susan L Slager; Neil E Kay
Familial chronic lymphocytic leukemia: what does it mean to me?
Clinical lymphoma & myeloma 2009;9 Suppl 3():S194-7.
2009: Neil E Kay
Circulating endothelial cells in chronic lymphocytic leukemia: more evidence of disturbed angiogenesis.
Leukemia & lymphoma 2009;50(1):8-9.
2008: Clive S Zent; Charla R Secreto; Betsy R LaPlant; Nancy D Bone; Timothy G Call; Tait D Shanafelt; Diane F Jelinek; Renee C Tschumper; Neil E Kay
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
Leukemia research 2008;32(12):1849-56.
2008: James Cerhan; Wen Liu; Zachary S Fredericksen; Anne J Novak; Julie M Cunningham; Neil E Kay; Ahmet Dogan; Mark Liebow; Alice H Wang; Timothy G Call; Thomas M Habermann; Stephen M Ansell; Susan L Slager
Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(11):3161-9.
2008: Clive S Zent; Timothy G Call; Tait D Shanafelt; Renee C Tschumper; Diane F Jelinek; Deborah A Bowen; Charla R Secreto; Betsy R Laplant; Brian Kabat; Neil E Kay
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
Cancer 2008;113(8):2110-8.
2008: Neil E Kay
Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O 2008;6(10):727-9.
2008: Grzegorz S Nowakowski; Debabrata Mukhopadhyay; Xiaosheng Wu; Neil E Kay
Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells.
Leukemia research 2008;32(10):1634-6.
2008: Tait D Shanafelt; Neil E Kay; Timothy G Call; Clive S Zent; Diane F Jelinek; Betsy LaPlant; William Morice; Curtis A Hanson
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?
Leukemia research 2008;32(9):1458-61.
2008: Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.
British journal of haematology 2008;141(5):607-14.
2008: Clive S Zent; Wei Ding; Susan M Schwager; Megan S Reinalda; James D Hoyer; Diane F Jelinek; Renee C Tschumper; Deborah A Bowen; Timothy G Call; Tait D Shanafelt; Neil E Kay; Susan L Slager
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma.
British journal of haematology 2008;141(5):615-21.
2008: Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Grzegorz S Nowakowski; Clive S Zent; Timothy G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.
British journal of haematology 2008;140(5):537-46.
2008: Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.
The Journal of clinical investigation 2008;118(1):306-15.
2007: James Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu; William R Macon; Diane F Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.
Blood 2007;110(13):4455-63.
2007: Deborah A Bowen; Timothy G Call; Greg D Jenkins; Clive S Zent; Susan Schwager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features.
Leukemia & lymphoma 2007;48(12):2412-7.
2007: Susan L Slager; Neil E Kay; Zachary S Fredericksen; Alice H Wang; Mark Liebow; Julie M Cunningham; Celine M Vachon; Timothy G Call; James Cerhan
Susceptibility genes and B-chronic lymphocytic leukaemia.
British journal of haematology 2007;139(5):762-71.
2007: Rebekah L Browning; Susan M Geyer; Amy J Johnson; Diane F Jelinek; Renee C Tschumper; Timothy G Call; Tait D Shanafelt; Clive S Zent; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Michael R Grever; Neil E Kay; John C Byrd; David M Lucas
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.
Leukemia research 2007;31(12):1737-40.
2007: Kami Maddocks-Christianson; Susan L Slager; Clive S Zent; Megan S Reinalda; Timothy G Call; Thomas M Habermann; Deborah A Bowen; James D Hoyer; Susan Schwager; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
British journal of haematology 2007;139(3):398-404.
2007: Tait D Shanafelt; Deborah Bowen; Chaya Venkat; Susan L Slager; Clive S Zent; Neil E Kay; Megan S Reinalda; Jeff A Sloan; Timothy G Call
Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients.
British journal of haematology 2007;139(2):255-64.
2007: Clive S Zent; Neil E Kay
Chronic lymphocytic leukemia: biology and current treatment.
Current oncology reports 2007;9(5):345-52.
2007: Neil E Kay; S M O'Brien; A R Pettitt; S Stilgenbauer
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.
Leukemia 2007;21(9):1885-91.
2007: Tait D Shanafelt; Neil E Kay
Combination therapies for previously untreated CLL.
Lancet 2007;370(9583):197-8.
2007: Andrei V Ougolkov; Nancy D Bone; Martin E Fernandez Zapico; Neil E Kay; Daniel D Billadeau
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.
Blood 2007;110(2):735-42.
2007: Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".
Leukemia research 2007;31(7):899-906.
2007: Tait D Shanafelt; Thomas Lin; Susan M Geyer; Clive S Zent; Nelson Leung; Brian Kabat; Deborah Bowen; Michael R Grever; John C Byrd; Neil E Kay
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
Cancer 2007;109(11):2291-8.
2007: Grzegorz S Nowakowski; James D Hoyer; Tait D Shanafelt; Susan M Geyer; Betsy R LaPlant; Timothy G Call; Diane F Jelinek; Clive S Zent; Neil E Kay
Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test.
Mayo Clinic proceedings. Mayo Clinic 2007;82(4):449-53.
2007: William Martin; Roshini Abraham; Tait D Shanafelt; Raynell J Clark; Nancy D Bone; Susan M Geyer; Jerry A Katzmann; Arthur R Bradwell; Neil E Kay; Thomas E Witzig
Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Translational research : the journal of laboratory and clinical medicine 2007;149(4):231-5.
2007: Neil E Kay; Tait D Shanafelt
Prognostic factors in chronic lymphocytic leukemia.
Current hematologic malignancy reports 2007;2(1):49-55.
2007: Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee C Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Blood 2007;109(2):405-11.
2007: Priyabrata Mukherjee; Resham Bhattacharya; Nancy D Bone; Yean K Lee; Chitta Ranjan Patra; Shanfeng Wang; Lichun Lu; Charla Secreto; Pataki C Banerjee; Michael J Yaszemski; Neil E Kay; Debabrata Mukhopadhyay
Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis.
Journal of nanobiotechnology 2007;5():4.
2006: Neil E Kay; Kanti Rai; Susan O'Brien
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Clinical advances in hematology & oncology : H&O 2006;4(11 Suppl 22):1-10; quiz 11-2.
2006: Tait D Shanafelt; Thomas E Witzig; Stephanie R Fink; Robert B Jenkins; Sarah F Paternoster; Stephanie A Smoley; Kimberly J Stockero; Danielle M Nast; Heather C Flynn; Renee C Tschumper; Susan Geyer; Clive S Zent; Timothy G Call; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4634-41.
2006: Tait D Shanafelt; John C Byrd; Timothy G Call; Clive S Zent; Neil E Kay
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Annals of internal medicine 2006;145(6):435-47.
2006: Clive S Zent; Timothy G Call; William J Hogan; Tait D Shanafelt; Neil E Kay
Update on risk-stratified management for chronic lymphocytic leukemia.
Leukemia & lymphoma 2006;47(9):1738-46.
2006: Tait D Shanafelt; Diane F Jelinek; Renee C Tschumper; Susan Schwager; Grzegorz S Nowakowski; Gordon W Dewald; Neil E Kay
Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3218-9; author reply 3219-20.
2006: Stephanie R Fink; Stephanie A Smoley; Kimberly J Stockero; Sarah F Paternoster; Erik C Thorland; Daniel L Van Dyke; Tait D Shanafelt; Clive S Zent; Timothy G Call; Neil E Kay; Gordon W Dewald
Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2006;167(2):177-81.
2006: Tait D Shanafelt; Y K Lee; Timothy G Call; Grzegorz S Nowakowski; David Dingli; Clive S Zent; Neil E Kay
Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies.
Leukemia research 2006;30(6):707-12.
2006: Robert A Kyle; Traci Leong; Shuli Li; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Cancer 2006;106(9):1958-66.
2006: Kimberly J Stockero; Stephanie R Fink; Stephanie A Smoley; Sarah F Paternoster; Tait D Shanafelt; Timothy G Call; Clive S Zent; Daniel L Van Dyke; Neil E Kay; Gordon W Dewald
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2006;166(2):152-6.
2006: Tait D Shanafelt; Neil E Kay
The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.
Seminars in oncology 2006;33(2):174-85.
2006: Anne J Novak; Deanna M Grote; Steven C Ziesmer; Michael P Kline; Michelle K Manske; Susan Slager; Thomas E Witzig; Tait D Shanafelt; Timothy G Call; Neil E Kay; Diane F Jelinek; James Cerhan; Jane A Gross; Brandon Harder; Stacey R Dillon; Stephen M Ansell
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):983-7.
2005: Brian T Pittner; Tait D Shanafelt; Neil E Kay; Diane F Jelinek
CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.
Leukemia 2005;19(12):2264-72.
2005: Neil E Kay; Nancy D Bone; Yean K Lee; Diane F Jelinek; Pamela Leland; Traci E Battle; David A Frank; Raj K Puri
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.
Leukemia research 2005;29(9):1009-18.
2005: David R Barnidge; Diane F Jelinek; David C Muddiman; Neil E Kay
Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents.
Journal of proteome research 2005;4(4):1310-7.
2005: Grzegorz S Nowakowski; Gordon W Dewald; James D Hoyer; Sarah F Paternoster; Kimberly J Stockero; Stephanie R Fink; Stephanie A Smoley; Ellen D Remstein; Robert L Phyliky; Timothy G Call; Tait D Shanafelt; Neil E Kay; Clive S Zent
Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.
British journal of haematology 2005;130(1):36-42.
2005: Jeffrey C Nolz; Renee C Tschumper; Brian T Pittner; Jaime R Darce; Neil E Kay; Diane F Jelinek
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.
Leukemia 2005;19(6):1018-24.
2005: David R Barnidge; Renee C Tschumper; Diane F Jelinek; David C Muddiman; Neil E Kay
Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;819(1):33-9.
2005: Neil E Kay; T Wasil
Survival of chronic lymphocytic leukemia cells: CD40L and the vascular endothelial growth factor (VEGF) connection.
Leukemia 2005;19(4):531-2.
2005: Yean K Lee; Tait D Shanafelt; Nancy D Bone; Ann K Strege; Diane F Jelinek; Neil E Kay
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.
Leukemia 2005;19(4):513-23.
2005: Stephanie R Fink; Sarah F Paternoster; Stephanie A Smoley; Heather C Flynn; Susan M Geyer; Tait D Shanafelt; You Kyoung Lee; Diane F Jelinek; Neil E Kay; Gordon W Dewald
Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.
Leukemia research 2005;29(3):253-62.
2005: Tait D Shanafelt; Yean K Lee; Nancy D Bone; Ann K Strege; Ven L Narayanan; Edward A Sausville; Susan M Geyer; Scott H Kaufmann; Neil E Kay
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.
Blood 2005;105(5):2099-106.
2004: Yean K Lee; Nancy D Bone; Ann K Strege; Tait D Shanafelt; Diane F Jelinek; Neil E Kay
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.
Blood 2004;104(3):788-94.
2004: Irene M Ghobrial; Nancy D Bone; Mary J Stenson; Anne J Novak; Karen E Hedin; Neil E Kay; Stephen M Ansell
Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
Mayo Clinic proceedings. Mayo Clinic 2004;79(3):318-25.
2004: Tait D Shanafelt; Susan M Geyer; Neil E Kay
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.
Blood 2004;103(4):1202-10.
2004: Clive S Zent; Neil E Kay
Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O 2004;2(2):107-13.
2004: Brian T Pittner; Diane F Jelinek; Neil E Kay
CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL.
Leukemia 2004;18(1):180-2.
2003: Joya Chandra; Jennifer S Hackbarth; Son B Le; David Loegering; Nancy D Bone; Laura M Bruzek; Ven L Narayanan; Alex A. Adjei; Neil E Kay; Ayalew Tefferi; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.
Blood 2003;102(13):4512-9.
2003: Neil E Kay; Brian T Pittner
IL-4 biology: impact on normal and leukemic CLL B cells.
Leukemia & lymphoma 2003;44(6):897-903.
2003: Gordon W Dewald; Stephanie R Brockman; Sarah F Paternoster; Nancy D Bone; Judith R O'Fallon; Cristine Allmer; C David James; Diane F Jelinek; Renee C Tschumper; Curtis A Hanson; Rajiv K Pruthi; Thomas E Witzig; Timothy G Call; Neil E Kay
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.
British journal of haematology 2003;121(2):287-95.
2003: Diane F Jelinek; Renee C Tschumper; Gustavo Stolovitzky; Stephen J Iturria; Yuhai Tu; Jorge Lepre; Nigam Shah; Neil E Kay
Identification of a global gene expression signature of B-chronic lymphocytic leukemia.
Molecular cancer research : MCR 2003;1(5):346-61.
2002: Anne J Novak; Richard J Bram; Neil E Kay; Diane F Jelinek
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.
Blood 2002;100(8):2973-9.
2002: Rafael Fonseca; Emily Blood; Martin M Oken; Robert A Kyle; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; James D Hoyer; David Harrington; Neil E Kay; Brian Van Ness; Philip R Greipp
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Blood 2002;99(10):3735-41.
2002: Neil E Kay; Nancy D Bone; Renee C Tschumper; K H Howell; Susan M Geyer; Gordon W Dewald; Curtis A Hanson; Diane F Jelinek
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
Leukemia 2002;16(5):911-9.
2002: Rafael Fonseca; David Harrington; Martin M Oken; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Emily Blood; S Vincent Rajkumar; Neil E Kay; Brian Van Ness; Philip R Greipp
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Cancer research 2002;62(3):715-20.
2001: Diane F Jelinek; Renee C Tschumper; Susan M Geyer; Nancy D Bone; Gordon W Dewald; Curtis A Hanson; Mary J Stenson; Thomas E Witzig; A Tefferi; Neil E Kay
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.
British journal of haematology 2001;115(4):854-61.
2001: Neil E Kay; D F Jelinek; L Peterson
Angiogenesis in B-chronic lymphocytic leukemia.
Leukemia research 2001;25(8):709-10.
2001: Neil E Kay; TL Leong; Nancy D Bone; D H Vesole; Philip R Greipp; Brian Van Ness; Martin M Oken; R A Kyle
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.
Blood 2001;98(1):23-8.
2001: Rafael Fonseca; Martin M Oken; David Harrington; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Neil E Kay; Brian Van Ness; Philip R Greipp; Gordon W Dewald
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.
Leukemia 2001;15(6):981-6.
2001: Neil E Kay; D F Jelinek; L Peterson
Angiogenesis in B-chronic lymphocytic leukemia.
Leukemia research 2001;25(6):485-6.
2001: Neil E Kay; L Han; Nancy D Bone; G Williams
Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.
British journal of haematology 2001;112(3):760-7.
2000: Rafael Fonseca; Mike C Trendle; Traci Leong; Robert A Kyle; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
British journal of haematology 2000;109(1):24-9.
1999: Martin M Oken; Traci Leong; R E Lenhard; Philip R Greipp; Neil E Kay; Brian Van Ness; R M Keimowitz; R A Kyle
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Cancer 1999;86(6):957-68.
1999: Philip R Greipp; Mike C Trendle; Traci Leong; Martin M Oken; Neil E Kay; Brian Van Ness; Robert A Kyle
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
Leukemia & lymphoma 1999;35(1-2):83-9.
1999: Mike C Trendle; TL Leong; Robert A Kyle; J A Katzmann; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.
American journal of hematology 1999;61(4):232-7.
1999: X Y Mu; MP Gosland; MM Bartik; J Schimmelpfennig; Neil E Kay
Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.
Journal of clinical immunology 1999;19(4):239-46.
1998: Philip R Greipp; TL Leong; J M Bennett; Philippe Gaillard; B Klein; James A Stewart; Martin M Oken; Neil E Kay; Brian Van Ness; Robert A Kyle
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
Blood 1998;91(7):2501-7.
1998: Neil E Kay; Traci Leong; Nancy D Bone; R A Kyle; Philip R Greipp; Brian Van Ness; Martin M Oken
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93.
British journal of haematology 1998;100(3):459-63.
1998: MM Bartik; D Welker; Neil E Kay
Impairments in immune cell function in B cell chronic lymphocytic leukemia.
Seminars in oncology 1998;25(1):27-33.
1997: Neil E Kay; TL Leong; R A Kyle; Philip R Greipp; Daniel D Billadeau; Brian Van Ness; Nancy D Bone; Martin M Oken
Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.
Blood 1997;90(1):340-5.
1997: X Mu; Neil E Kay; MP Gosland; C Darrell Jennings
Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells.
British journal of haematology 1997;96(4):733-5.
1996: P Liu; T Leong; L Quam; Daniel D Billadeau; Neil E Kay; Philip R Greipp; Robert A Kyle; Martin M Oken; Brian Van Ness
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Blood 1996;88(7):2699-706.
1996: Neil E Kay
Clinical utility of molecular probes in lymphoproliferative disorders.
Blood reviews 1996;10(2):81-8.
1996: Martin M Oken; Robert A Kyle; Philip R Greipp; Neil E Kay; A Tsiatis; S A Gregory; J Spiegel R; J O'Connell M
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Leukemia & lymphoma 1996;20(5-6):447-52.
1995: Neil E Kay; Martin M Oken; Nancy D Bone; Robert A Kyle; Philip R Greipp; Brian Van Ness; T Leong
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group.
Blood 1995;86(10):4000-1.
1995: Neil E Kay; E A Ranheim; L C Peterson
Tumor suppressor genes and clonal evolution in B-CLL.
Leukemia & lymphoma 1995;18(1-2):41-9.
1995: Neil E Kay; Martin M Oken; Robert A Kyle; Brian Van Ness; L Kalish; T Leong; Philip R Greipp
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.
Leukemia & lymphoma 1995;16(3-4):351-4.
1993: I Hings; Neil E Kay; E Ranheim; C Seroogy; R E Parson
Malignant B cell CD5 membrane phenotype and B cell colony growth in vivo and in vitro in patients with B-chronic lymphocytic leukemia: analysis with clinical parameters.
Leukemia & lymphoma 1993;12(1-2):59-67.
1993: Neil E Kay; R Suen; E Ranheim; L C Peterson
Confirmation of Rb gene defects in B-CLL clones and evidence for variable predominance of the Rb defective cells within the CLL clone.
British journal of haematology 1993;84(2):257-64.
1990: S L Zaknoen; Neil E Kay
Immunoregulatory cell dysfunction in chronic B-cell leukemias.
Blood reviews 1990;4(3):165-74.
1990: Neil E Kay; J E Morley; J I Allen
Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes.
Immunology 1990;70(4):485-91.
1990: Neil E Kay; Nancy D Bone; M Hupke; A P Dalmasso
Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male.
Blood 1990;75(10):2024-9.
1989: R T Perri; Neil E Kay
Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation.
American journal of hematology 1989;31(3):166-72.
1989: Neil E Kay; R T Perri
Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-cell immunoglobulin synthesis.
Blood 1989;73(4):1016-9.
1989: J D Burton; C H Weitz; Neil E Kay
Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function.
American journal of hematology 1989;30(2):61-7.
1988: Neil E Kay; J Burton; D Wagner; D L Nelson
The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors.
Blood 1988;72(2):447-50.
1988: Jeanette Mladenovic; Neil E Kay
Erythropoietin induces rapid increases in intracellular free calcium in human bone marrow cells.
The Journal of laboratory and clinical medicine 1988;112(1):23-7.
1988: Neil E Kay; R T Perri
Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia.
Clinics in laboratory medicine 1988;8(1):163-77.
1988: Neil E Kay; M M Oken; J J Mazza; E C Bradley
Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2.
Nouvelle revue française d'hématologie 1988;30(5-6):475-8.
1988: Neil E Kay; R T Perri
Natural killer function in B-chronic lymphocytic leukemia.
Nouvelle revue française d'hématologie 1988;30(5-6):343-5.
1987: J I Allen; H J Syropoulos; B Grant; J C Eagon; Neil E Kay
Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia.
The Journal of laboratory and clinical medicine 1987;109(4):396-401.
1987: R T Perri; Neil E Kay
Malignant chronic lymphocytic leukemia B cells express interleukin 2 receptors but fail to respond to interleukin 2's proliferative signal.
Leukemia 1987;1(2):127-30.
1986: R T Perri; Neil E Kay
Abnormal T cell function in early-stage chronic lymphocytic leukemia (CLL) patients.
American journal of hematology 1986;22(1):55-61.
1983: Neil E Kay; M M Oken; R T Perri
The influential T cell in B-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(12):810-6.
1983: J I Allen; R T Perri; C J McClain; Neil E Kay
Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency.
The Journal of laboratory and clinical medicine 1983;102(4):577-89.
1983: R T Perri; I Royston; T W LeBien; Neil E Kay
Chronic lymphocytic leukemia progenitor cells carry the antigens T65, BA-1, and Ia.
Blood 1983;61(5):871-5.
1982: J I Allen; W Korchik; Neil E Kay; C J McClain
Zinc and T-lymphocyte function in hemodialysis patients.
The American journal of clinical nutrition 1982;36(3):410-5.
1982: R T Perri; Neil E Kay; J McCarthy; R L Vessella; H S Jacob; L T Furcht
Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity.
Blood 1982;60(2):430-5.
1982: Neil E Kay; D E Holloway; S W Hutton; Nancy D Bone; William C Duane
Human T-cell function in experimental ascorbic acid deficiency and spontaneous scurvy.
The American journal of clinical nutrition 1982;36(1):127-30.
1982: R T Perri; M M Oken; Neil E Kay
Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.
The Journal of laboratory and clinical medicine 1982;99(4):512-9.
1982: R T Perri; Neil E Kay
Monoclonal CLL B-cells may be induced to grow in an in vitro B-cell colony assay system.
Blood 1982;59(2):247-9.